Private Equity Power Shift: TPG Sells Stake in Sai Life Sciences—Share Price Takes a Hit

In a significant development in the Indian pharma outsourcing sector, global private equity giant TPG Asia has divested its entire stake in Sai Life Sciences through bulk block deals on August 26, 2025. The sale involved around 30.7 million shares, representing roughly 14.7% of the company's equity capital, valued at approximately ₹2,500 crore. This exit marks a major reshuffle in the shareholder base of the Hyderabad-based contract research, development, and manufacturing organization (CRDMO), sending ripples across the stock market and among institutional investors.

 

Key Highlights:

Background and Transaction Details

TPG Asia VII SF PTE Ltd, the investment arm holding a significant stake of 15.2% in Sai Life Sciences, initiated this clean exit through the sale of 3.07 crore shares via block deals on the stock exchanges. The floor price was set at ₹860 per share — offering buyers a roughly 5% discount compared to the stock’s last traded price. The deal size translates to nearly ₹2,500 crore in value, signaling a large cash-out by the private equity investor after years of involvement in the company.

 

Market Impact and Share Price Movement

Following the block deal announcement and completion, Sai Life Sciences’ shares dropped by nearly 4%, hitting around ₹870 during early trading on August 26. Heavy volumes accompanied this price dip, with over 20 lakh shares changing hands, vastly above the two-week trading average. The company’s market cap correspondingly slipped by approximately ₹629 crore due to the sell-off.

 

Despite this immediate share price correction, analysts note the transaction as a normal private equity exit rather than a reflection of Sai Life Sciences' fundamentals. The stock has shown strong momentum, having rallied over 25% in the past quarter, driven by robust operational performance and growth projections.

 

Growth Outlook and Strategic Positioning

Sai Life Sciences has been benefiting from its expanding role in the global pharmaceutical outsourcing ecosystem, reporting strong quarterly results recently. The company posted a 77% revenue increase to ₹496 crore and an expanded EBITDA margin of 25%, underscoring its improving profitability. Management projects an ambitious revenue compounded annual growth rate (CAGR) of 15-20% over the next 3-5 years, backed by expanding manufacturing and research capabilities.

 

Sector experts believe Sai Life Sciences is well-positioned to capitalize on the growing demand for contract research and manufacturing from multinational pharma companies seeking cost-efficient and high-capacity partners in India.

 

Institutional Interest and Next Steps

The exit of TPG Asia is expected to open the doors for other marquee investors to acquire stakes, possibly both domestic mutual funds and foreign institutional buyers, although the exact identities of the buyers in this deal remain undisclosed. Previous incremental stake sales by TPG included purchases by Norges Bank and leading Indian mutual funds, indicating continued strong institutional appetite.

 

Investors will keenly watch the post-exit shareholder structure and any strategic shifts in Sai Life Sciences, as well as how the company manages growth momentum in the highly competitive CRDMO space going forward.

 

Summary

TPG Asia’s bulk sale of 30.7 million Sai Life Sciences shares for about ₹2,500 crore marks a major private equity exit that triggered a short-term share price dip of nearly 4% in India’s pharma outsourcing market leader. Despite the market reaction, the company retains promising growth prospects fueled by strong financials and increasing global demand. Upcoming quarters will be crucial for tracking how Sai Life Sciences consolidates its position with a reshaped investor base and sustains its performance trajectory.

 

Source: Reuters, Fortune India, Economic Times, Business Standard reports